Anti-Pseudomonas immunoglobulin. III. Preliminary clinical evaluation.
Preliminary clinical evaluation of sheep anti-Pseudomonas immunoglobulin was performed on 20 burn injured patients. The patients were divided into two comparable groups of ten persons. One group was treated with the immunoglobulin shortly after thermal injury (in about two days). The patients of the second group received this preparation in about 18 days post thermal injury. It was concluded that the sheep anti-Pseudomonas immunoglobulin is well tolerated by patients. The results of clinical observations show that, in respect to incidence of sepsis and survival, only early administration of immunoglobulin can prevent further development of infection caused by Pseudomonas aeruginosa.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000907:Antibodies, Bacterial / Q000008:administration & dosage* / Q000096:biosynthesis; D002056:Burns / Q000150:complications / Q000401:mortality / Q000628:therapy*; D002675:Child, Preschool; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects; D007136:Immunoglobulins / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011044:Poland; D011552:Pseudomonas Infections / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000254:growth & development / Q000276:immunology; D018805:Sepsis / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D012756:Sheep
D000907:Antibodies, Bacterial; D007136:Immunoglobulins